Frontline Alectinib Upholds OS Benefit in Advanced ALK+ NSCLC - CancerNetwork

Frontline Alectinib Upholds OS Benefit in Advanced ALK+ NSCLC  CancerNetwork

Adjuvant Alectinib Impresses in Updated ALINA Results for ALK+ NSCLC - OncLive

Adjuvant Alectinib Impresses in Updated ALINA Results for ALK+ NSCLC  OncLive

Alectinib in combination with bevacizumab as first-line treatment in ALK -rearranged non-small ce...

Alectinib in combination with bevacizumab as first-line treatment in ALK -rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial  Nature

Implications of the ALINA Trial: Is It Time to Skip Adjuvant Chemotherapy in ALK-Positive NSCLC? ...

Implications of the ALINA Trial: Is It Time to Skip Adjuvant Chemotherapy in ALK-Positive NSCLC?  ASCO Daily News

ALEX Trial Final Results at ESMO 2025: Alectinib Demonstrates Durable Overall Survival and Long-T...

ALEX Trial Final Results at ESMO 2025: Alectinib Demonstrates Durable Overall Survival and Long-Term Disease Control in Advanced ALK-Positive NSCLC  Oncodaily

Adjuvant ALK TKIs show robust and durable disease-free survival benefit in non-small cell lung ca...

Adjuvant ALK TKIs show robust and durable disease-free survival benefit in non-small cell lung cancer  ESMO Daily Reporter

Perforation of the descending colon induced by alectinib in a patient with non-small cell lung ca...

Perforation of the descending colon induced by alectinib in a patient with non-small cell lung cancer: a Case Report  Frontiers

Study Investigates Alectinib Versus Crizotinib in the Adjuvant Setting for Patients With ALK+ NSC...

Study Investigates Alectinib Versus Crizotinib in the Adjuvant Setting for Patients With ALK+ NSCLC  Cancer Nursing Today

Alecensa Improves 4-Year Survival in Early ALK-Positive Lung Cancer - Cure Today

Alecensa Improves 4-Year Survival in Early ALK-Positive Lung Cancer  Cure Today

'Blow Your Mind' Survival Improvement in Advanced, Mutated NSCLC - MedPage Today

'Blow Your Mind' Survival Improvement in Advanced, Mutated NSCLC  MedPage Today

Advanced ALK-Positive NSCLC: Treatment Sequencing Insights From ASCO 2025 - Cancer Therapy Advisor

Advanced ALK-Positive NSCLC: Treatment Sequencing Insights From ASCO 2025  Cancer Therapy Advisor

Oncology Letters - Spandidos Publications

Oncology Letters  Spandidos Publications

Neoadjuvant Alectinib Effective, Tolerable in Late-Stage ALK-Positive NSCLC - CancerNetwork

Neoadjuvant Alectinib Effective, Tolerable in Late-Stage ALK-Positive NSCLC  CancerNetwork

Phase III ALINA Trial Shows Adjuvant Alectinib Has ‘Clinically Meaningful’ Benefits for ALK+ NSCL...

Phase III ALINA Trial Shows Adjuvant Alectinib Has ‘Clinically Meaningful’ Benefits for ALK+ NSCLC  Cancer Nursing Today

Computational drug repurposing reveals Alectinib as a potential lead targeting Cathepsin S for th...

Computational drug repurposing reveals Alectinib as a potential lead targeting Cathepsin S for therapeutic developments against cancer and chronic pain  Frontiers

Dr Mok on Final OS Data From the ALEX Study Evaluating First-Line Alectinib in ALK+ NSCLC - OncLive

Dr Mok on Final OS Data From the ALEX Study Evaluating First-Line Alectinib in ALK+ NSCLC  OncLive

Case Report: Successful late-line pralsetinib treatment in an ALK-rearranged lung adenocarcinoma ...

Case Report: Successful late-line pralsetinib treatment in an ALK-rearranged lung adenocarcinoma patient with KIF5B-RET fusion resistant to alectinib  Frontiers

Dr Lee on Disease-Free Survival Outcomes With Alectinib in ALK+ NSCLC - OncLive

Dr Lee on Disease-Free Survival Outcomes With Alectinib in ALK+ NSCLC  OncLive

CCN1 is a therapeutic target upregulated in EML4-ALK mutant lung adenocarcinoma reversibly resist...

CCN1 is a therapeutic target upregulated in EML4-ALK mutant lung adenocarcinoma reversibly resistant to alectinib  Nature

Postoperative Crizotinib Fails in Early Lung Cancer - MedPage Today

Postoperative Crizotinib Fails in Early Lung Cancer  MedPage Today

Exploring First-Line ALK Inhibitors, TKI Sequencing in ALK-Positive NSCLC - CancerNetwork

Exploring First-Line ALK Inhibitors, TKI Sequencing in ALK-Positive NSCLC  CancerNetwork

FDA Approves Alectinib for ALK-Positive Lung Cancer - National Cancer Institute (.gov)

FDA Approves Alectinib for ALK-Positive Lung Cancer  National Cancer Institute (.gov)

ALNEO Phase II Trial Highlights Promising Role of Perioperative Alectinib in Stage III Resectable...

ALNEO Phase II Trial Highlights Promising Role of Perioperative Alectinib in Stage III Resectable ALK-Positive NSCLC  Oncodaily

Study Compares Effectiveness of First-Line TKIs in Patients With ALK+ NSCLC and Brain Metastases ...

Study Compares Effectiveness of First-Line TKIs in Patients With ALK+ NSCLC and Brain Metastases  Cancer Nursing Today

Navigating EGFR Mutations and ALK Fusions in Early-Stage Non-Small Cell Lung Cancer - Pharmacy Times

Navigating EGFR Mutations and ALK Fusions in Early-Stage Non-Small Cell Lung Cancer  Pharmacy Times

In Early NSCLC, Biomarker Testing Appears to Be Underused - Physician's Weekly

In Early NSCLC, Biomarker Testing Appears to Be Underused  Physician's Weekly

Luis Lara-Mejía: Early Resistance in ALK+ NSCLC Targeted with Alectinib and Bevacizumab Combo - O...

Luis Lara-Mejía: Early Resistance in ALK+ NSCLC Targeted with Alectinib and Bevacizumab Combo  Oncodaily

Alectinib approved in Scotland for ALK+ lung cancer post-surgery - ALK Positive Lung Cancer UK - ...

Alectinib approved in Scotland for ALK+ lung cancer post-surgery - ALK Positive Lung Cancer UK  Oncodaily

Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer - The New England Journal of Medicine

Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer  The New England Journal of Medicine

From Cholesterol Management to Self-Image Concerns: What Nurses Should Know About ALK+ NSCLC - Ca...

From Cholesterol Management to Self-Image Concerns: What Nurses Should Know About ALK+ NSCLC  Cancer Nursing Today

Dr Nieva on the Rationale for Comparing ALK Inhibitors in ALK+ NSCLC - OncLive

Dr Nieva on the Rationale for Comparing ALK Inhibitors in ALK+ NSCLC  OncLive

Alectinib Reduces Risk of Recurrence or Death by 76% in Early-Stage, Resected, ALK+ NSCLC - Oncol...

Alectinib Reduces Risk of Recurrence or Death by 76% in Early-Stage, Resected, ALK+ NSCLC  Oncology Nursing News

Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer - The New Engla...

Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer  The New England Journal of Medicine

FDA Approves Alectinib For Initial Treatment of ALK-Positive Lung Cancer - National Cancer Instit...

FDA Approves Alectinib For Initial Treatment of ALK-Positive Lung Cancer  National Cancer Institute (.gov)

Alectinib and Pembrolizumab for Non-Small Cell Lung Cancers - Medscape

Alectinib and Pembrolizumab for Non-Small Cell Lung Cancers  Medscape

Appendicitis while on alectinib for non-small cell lung cancer: a tale of two case reports - Fron...

Appendicitis while on alectinib for non-small cell lung cancer: a tale of two case reports  Frontiers

CROWN Trial 5-Year Update: Lorlatinib Is the Frontrunner in the Frontline Setting - ASCO Daily News

CROWN Trial 5-Year Update: Lorlatinib Is the Frontrunner in the Frontline Setting  ASCO Daily News

Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunit...

Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity  Nature

Brigatinib, Alectinib Produce Similar PFS After NSCLC Progression on Crizotinib - Cancer Therapy ...

Brigatinib, Alectinib Produce Similar PFS After NSCLC Progression on Crizotinib  Cancer Therapy Advisor

Adjuvant Alectinib Earns European Approval in Resectable ALK+ NSCLC - CancerNetwork

Adjuvant Alectinib Earns European Approval in Resectable ALK+ NSCLC  CancerNetwork

Changes in Red Cell Morphology and Haematological Laboratory Parameters Associated With Alectinib...

Changes in Red Cell Morphology and Haematological Laboratory Parameters Associated With Alectinib  Wiley Online Library

Brigatinib Not Superior to Alectinib in ALK-Positive NSCLC - Targeted Oncology

Brigatinib Not Superior to Alectinib in ALK-Positive NSCLC  Targeted Oncology

Fibroblasts and alectinib switch the evolutionary games played by non-small cell lung cancer - Na...

Fibroblasts and alectinib switch the evolutionary games played by non-small cell lung cancer  Nature

Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive ...

Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study  The Lancet

YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptot...

YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation  Nature

Adjuvant Alectinib Is Associated With a Tolerable Safety Profile in ALK+ NSCLC - OncLive

Adjuvant Alectinib Is Associated With a Tolerable Safety Profile in ALK+ NSCLC  OncLive

FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer based on...

FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer based on ALINA trial  Oncodaily

Adjuvant alectinib is a new treatment strategy for resected ALK-positive NSCLC - ESMO Daily Reporter

Adjuvant alectinib is a new treatment strategy for resected ALK-positive NSCLC  ESMO Daily Reporter

FDA Approves Adjuvant Alectinib for ALK+ Early-Stage NSCLC - OncLive

FDA Approves Adjuvant Alectinib for ALK+ Early-Stage NSCLC  OncLive

FDA Approves Alectinib for Early-Stage ALK+ NSCLC - CancerNetwork

FDA Approves Alectinib for Early-Stage ALK+ NSCLC  CancerNetwork

FDA Approves Alectinib to Treat Patients With ALK-Positive NSCLC - Pharmacy Times

FDA Approves Alectinib to Treat Patients With ALK-Positive NSCLC  Pharmacy Times

ASCO 2025 / Promising new targeted therapy in very rare pediatric cancers - Institut Curie - Espa...

ASCO 2025 / Promising new targeted therapy in very rare pediatric cancers  Institut Curie - Espace presse

Alectinib Approved for ALK-Positive Adjuvant NSCLC - Medscape

Alectinib Approved for ALK-Positive Adjuvant NSCLC  Medscape

Adjuvant alectinib has been approved by the FDA for resected ALK-positive NSCLC - ESMO Daily Repo...

Adjuvant alectinib has been approved by the FDA for resected ALK-positive NSCLC  ESMO Daily Reporter

Alectinib Significantly Improves DFS Vs Chemo in Resected ALK+ NSCLC - CancerNetwork

Alectinib Significantly Improves DFS Vs Chemo in Resected ALK+ NSCLC  CancerNetwork

Phase 3 ALINA Study of Alectinib Shows DFS Benefit in ALK+ NSCLC - Targeted Oncology

Phase 3 ALINA Study of Alectinib Shows DFS Benefit in ALK+ NSCLC  Targeted Oncology

Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an...

Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial  The Lancet

Dramatic response to alectinib in a patient with ALK -rearranged squamous cell lung cancer - Wile...

Dramatic response to alectinib in a patient with ALK -rearranged squamous cell lung cancer  Wiley Online Library

Adjuvant Alectinib Approved in Europe for ALK+ Early-Stage NSCLC - OncLive

Adjuvant Alectinib Approved in Europe for ALK+ Early-Stage NSCLC  OncLive

Exceptional response to alectinib for duodenal carcinoma with ALK fusion: A case report and liter...

Exceptional response to alectinib for duodenal carcinoma with ALK fusion: A case report and literature review  Frontiers

Alectinib shows benefit across genetic profiles in resected ALK-positive NSCLC - ESMO Daily Reporter

Alectinib shows benefit across genetic profiles in resected ALK-positive NSCLC  ESMO Daily Reporter

Alectinib Fails to Boost Overall Survival in ALK-Positive Non-Small Cell Lung Cancer - CancerNetwork

Alectinib Fails to Boost Overall Survival in ALK-Positive Non-Small Cell Lung Cancer  CancerNetwork

Case Report: Pathological Complete Response to Neoadjuvant Alectinib in a Patient With Resectable...

Case Report: Pathological Complete Response to Neoadjuvant Alectinib in a Patient With Resectable ALK-Positive Non-Small Cell Lung Cancer  Frontiers

Alecensa (alectinib): Side effects, dosage, and more - Medical News Today

Alecensa (alectinib): Side effects, dosage, and more  Medical News Today

VisualAbstract: Alectinib Improves Disease-Free Survival in ALK-Positive Non-Small-Cell Lung Canc...

VisualAbstract: Alectinib Improves Disease-Free Survival in ALK-Positive Non-Small-Cell Lung Cancer Compared to Platinum-Based Chemotherapy  2 Minute Medicine

These 33 Life-Saving Drugs, Including Daratumumab, Alectinib, Obinutuzumab, Now GST-Free, See Lis...

These 33 Life-Saving Drugs, Including Daratumumab, Alectinib, Obinutuzumab, Now GST-Free, See List  Medical Dialogues

Alectinib Deemed “Highly Promising” for Pediatric ALK Fusion-Positive Cancers - Cancer Therapy Ad...

Alectinib Deemed “Highly Promising” for Pediatric ALK Fusion-Positive Cancers  Cancer Therapy Advisor

Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-pos...

Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer  Nature

ALINA Trial: Adjuvant Alectinib Improves Survival vs Platinum-Based Chemotherapy in ALK -Positive...

ALINA Trial: Adjuvant Alectinib Improves Survival vs Platinum-Based Chemotherapy in ALK -Positive NSCLC  The ASCO Post

Time to Response in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Ce...

Time to Response in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib in the Phase II NP28673 and NP28761 Studies  Oncology Nurse Advisor

Diet May Have Big Effect on Common Lung Cancer Treatment - Inside Precision Medicine

Diet May Have Big Effect on Common Lung Cancer Treatment  Inside Precision Medicine

Complete response to alectinib in ALK-fusion metastatic salivary ductal carcinoma - Nature

Complete response to alectinib in ALK-fusion metastatic salivary ductal carcinoma  Nature

Alectinib for Relapsed/Refractory ALK+ NSCLC - OncLive

Alectinib for Relapsed/Refractory ALK+ NSCLC  OncLive

Intracranial efficacy of alectinib in ALK-positive non-small cell lung cancer - 2 Minute Medicine

Intracranial efficacy of alectinib in ALK-positive non-small cell lung cancer  2 Minute Medicine

Alectinib Shows Activity in ALK-Rearranged Advanced Solid Tumors - Targeted Oncology

Alectinib Shows Activity in ALK-Rearranged Advanced Solid Tumors  Targeted Oncology

Updated Phase 3 ALEX Trial Data Finds Alectinib Maintains Significant Benefit in ALK+ NSCLC - Can...

Updated Phase 3 ALEX Trial Data Finds Alectinib Maintains Significant Benefit in ALK+ NSCLC  CancerNetwork

A New Molecularly Targeted Therapy for Lung Cancer - American Association for Cancer Research (AACR)

A New Molecularly Targeted Therapy for Lung Cancer  American Association for Cancer Research (AACR)

Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro in vivo...

Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro in vivo and ex vivo  Nature

Alectinib Yields Better Overall Survival Than Ceritinib in ALK-Positive Non–Small Cell Lung Cance...

Alectinib Yields Better Overall Survival Than Ceritinib in ALK-Positive Non–Small Cell Lung Cancer  CancerNetwork

Alectinib Lands FDA Approval for Adjuvant Therapy in NSCLC - MedPage Today

Alectinib Lands FDA Approval for Adjuvant Therapy in NSCLC  MedPage Today

Cancer drug alectinib less effective when taken with low-fat yogurt - Healio

Cancer drug alectinib less effective when taken with low-fat yogurt  Healio

Profound and sustained response with next-generation ALK inhibitors in patients with relapsed or ...

Profound and sustained response with next-generation ALK inhibitors in patients with relapsed or progressive ALK-positive anaplastic large cell lymphoma with central nervous system involvement  Haematologica

Alectinib Approved for ALK-Positive NSCLC - National Cancer Institute (.gov)

Alectinib Approved for ALK-Positive NSCLC  National Cancer Institute (.gov)

Anaplastic Lymphoma Kinase (ALK) Mutation-Targeting Treatment With Alectinib in Lung Adenocarcino...

Anaplastic Lymphoma Kinase (ALK) Mutation-Targeting Treatment With Alectinib in Lung Adenocarcinoma and Primary Cutaneous Marginal Zone B-Cell Lymphoma  Cureus

Visualizing spatial distribution of alectinib in murine brain using quantitative mass spectrometr...

Visualizing spatial distribution of alectinib in murine brain using quantitative mass spectrometry imaging  Nature

Alectinib superior to chemotherapy in advanced ALK + NSCLC - The Lancet

Alectinib superior to chemotherapy in advanced ALK + NSCLC  The Lancet

Lorlatinib in the second line and beyond for ALK positive lung cancer: real-world data from resou...

Lorlatinib in the second line and beyond for ALK positive lung cancer: real-world data from resource-constrained settings  Nature

Alectinib Found Active in Advanced ALK-Positive Advanced NSCLC Characterized by Crizotinib Resist...

Alectinib Found Active in Advanced ALK-Positive Advanced NSCLC Characterized by Crizotinib Resistance Mutations  Cancer Therapy Advisor

Substantial Meals Can Elevate Lung Cancer Drug Concentration - Cure Today

Substantial Meals Can Elevate Lung Cancer Drug Concentration  Cure Today

Anthem Biosciences tells Delhi High Court it won't launch products using anti-cancer drug Alectin...

Anthem Biosciences tells Delhi High Court it won't launch products using anti-cancer drug Alectinib  Bar and Bench

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Posi...

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells  Frontiers

Salvage Surgery Following First-Line Alectinib for ALK-Rearranged NSCLC: Perioperative Outcomes &...

Salvage Surgery Following First-Line Alectinib for ALK-Rearranged NSCLC: Perioperative Outcomes & Pathological Response  Physician's Weekly

Alectinib Improves DFS Over Chemotherapy in Early-Stage, ALK+ NSCLC - Oncology News Central

Alectinib Improves DFS Over Chemotherapy in Early-Stage, ALK+ NSCLC  Oncology News Central

Alectinib (Alecensa) - Oncology Nurse Advisor

Alectinib (Alecensa)  Oncology Nurse Advisor

Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib i...

Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK -positive NSCLC  Nature

Mechanisms of synergistic suppression of ALK-positive lung cancer cell growth by the combination ...

Mechanisms of synergistic suppression of ALK-positive lung cancer cell growth by the combination of ALK and SHP2 inhibitors  Nature

FDA Approves Alectinib for ALK-Positive NSCLC - OncLive

FDA Approves Alectinib for ALK-Positive NSCLC  OncLive

First-Line ALK-Positive NSCLC With CNS Metastases at Baseline - The ASCO Post

First-Line ALK-Positive NSCLC With CNS Metastases at Baseline  The ASCO Post

Roche wins second FDA label expansion for Alecensa in NSCLC - Pharmaceutical Technology

Roche wins second FDA label expansion for Alecensa in NSCLC  Pharmaceutical Technology

Remarkable response to alectinib for metastatic papillary thyroid cancer with STRN-ALK fusion: A ...

Remarkable response to alectinib for metastatic papillary thyroid cancer with STRN-ALK fusion: A case report  Frontiers